Daa Pangenotypic Mavyret denied as non-formulary by Aetna?

Aetna's specific coverage criteria for daa pangenotypic mavyret are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Mavyret as Non-Formulary

Aetna's commercial formularies tier direct-acting antivirals (DAAs) differently across plan types and plan years. Mavyret (glecaprevir/pibrentasvir) may be placed on a non-preferred tier or excluded from a specific plan's formulary entirely, while a competing pangenotypic DAA occupies the preferred slot. The denial does not mean the drug is clinically inappropriate — it means your plan's benefit design requires extra steps before coverage is authorized.

## Why This Denial Is Appealable

Formulary exclusions are not absolute. Federal parity rules and state continuity-of-care protections require plans to offer a coverage exception process when a non-formulary drug is medically necessary. If your prescriber documents that the preferred formulary alternative is clinically unsuitable for your specific case, Aetna must consider that exception request.

## Federal Appeal Framework

• ACA §2719 / ERISA §503: Full-and-fair internal review is required, followed by an independent external review if the internal appeal is denied.
• Timeline: File the internal appeal within 180 days of the denial notice. External review must generally be requested within 4 months of an internal denial.
• Expedited option: Available when delay poses serious health risk; decisions typically required within 72 hours.

## The Appeal Process

1. Confirm which Aetna-preferred DAA sits on your plan's formulary and why your prescriber considers it inappropriate for your case. 2. Request a formulary exception simultaneously with — or immediately before — the internal appeal; Aetna is required to have an exception process. 3. Submit the internal appeal with supporting clinical documentation and a prescriber letter explaining why the preferred alternative cannot be used. 4. If denied, escalate to independent external review.

## Documentation to Gather

• Diagnosis and genotype: Lab confirmation of active HCV infection and genotype.
• Clinical rationale for Mavyret specifically: Prescriber letter explaining why the formulary-preferred DAA is contraindicated, likely to be ineffective, or otherwise unsuitable — referencing the FDA-approved labeling and the applicable professional society guideline organization (e.g., AASLD/IDSA HCV guidance).
• Renal, hepatic, or drug-interaction profile: Chart notes documenting comorbidities or co-medications that affect DAA selection, per the prescribing label.
• Prior DAA history: If any prior DAA was tried and failed or caused adverse effects, document dates, doses, and outcomes.

## Criteria-Mapping Structure

Build a two-column table. Left column: each requirement from Aetna's formulary exception or coverage policy. Right column: the specific chart fact, date, and document satisfying each requirement. Pay particular attention to the "clinical alternative is unsuitable" criterion — that is the pivot point of every non-formulary exception appeal.